おすすめの製品
由来生物
mouse
品質水準
抗体製品の状態
purified immunoglobulin
抗体製品タイプ
primary antibodies
クローン
2D4.2, monoclonal
化学種の反応性
human
メーカー/製品名
Chemicon®
テクニック
immunofluorescence: suitable
immunohistochemistry: suitable (paraffin)
western blot: suitable
アイソタイプ
IgG2a
輸送温度
wet ice
特異性
Reacts with a late protein M.W. 47-55 kD. Can detect CMV infection 24 hours post-infection exhibiting a cytoplasmic staining which reduces peak intensity at >72 hours.
With CMV the antigens expressed at different times are listed as:
Immediate Early (alpha gene expression): those antigens expressed at 3-12 hrs post-infection generally involved in Transcription such as 72kD major phosphoprotein and a few other other antigens at 60 - 80kD.
Early Antigen (beta genes) a.k.a. Delayed Early or Intermediate Early: expressed at 12-24hrs post-infection. Generally enzymes and one virion structural gene preceding viral DNA synthesis.
Late Antigen (gamma genes): expressed at 36-48hrs post-infection. Generally structural proteins. Major protein = 55kD
With CMV the antigens expressed at different times are listed as:
Immediate Early (alpha gene expression): those antigens expressed at 3-12 hrs post-infection generally involved in Transcription such as 72kD major phosphoprotein and a few other other antigens at 60 - 80kD.
Early Antigen (beta genes) a.k.a. Delayed Early or Intermediate Early: expressed at 12-24hrs post-infection. Generally enzymes and one virion structural gene preceding viral DNA synthesis.
Late Antigen (gamma genes): expressed at 36-48hrs post-infection. Generally structural proteins. Major protein = 55kD
免疫原
Epitope: late antigen
Sucrose gradient purified CMV AD169 (ATCC).
アプリケーション
Research Category
感染症
感染症
Research Sub Category
感染症-ウイルス
感染症-ウイルス
Anti-Cytomegalovirus Antibody, late antigen, clone 2D4.2 detects level of Cytomegalovirus & has been published & validated for use in IF, WB, IH(P).
IFA at 1:400-1:800 on acetone fixed cells.
Works on paraffin embedded tissue sections.
Dilute with buffer pH 7.4-7.6 to desired working volume.
For extensive dilution, protein containing or other stabilizing medium should be used.
Final working dilutions must be determined by end user.
Works on paraffin embedded tissue sections.
Dilute with buffer pH 7.4-7.6 to desired working volume.
For extensive dilution, protein containing or other stabilizing medium should be used.
Final working dilutions must be determined by end user.
物理的形状
Format: Purified
Purified immunoglobulin. Liquid in 0.02M PB with 0.25M NaCl, pH=7.6, 0.1% Sodium Azide.
保管および安定性
Maintain at +2-8°C for up to 12 months.
その他情報
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
法的情報
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our 製品選択ツール.
保管分類コード
10 - Combustible liquids
WGK
WGK 2
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
MAB8126:
試験成績書(COA)
製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Development of models and detection methods for different forms of cytomegalovirus for the evaluation of viral inactivation agents.
Transfusion null
American journal of physiology. Lung cellular and molecular physiology, 294(6), L1119-L1126 (2008-04-09)
Recent evidence suggests that dysfunctional type II alveolar epithelial cells (AECs) contribute to the pathogenesis of idiopathic pulmonary fibrosis (IPF). Based on the hypothesis that disease-causing mutations in surfactant protein C (SFTPC) provide an important paradigm for studying IPF, we
PloS one, 9(9), e108861-e108861 (2014-10-01)
Human cytomegalovirus (HCMV) has been indicated being a significant oncomodulator. Recent reports have suggested that an antiviral treatment alters the outcome of a glioblastoma. We analysed the performance of commercial HCMV-antibodies applying the immunohistochemical (IHC) methods on brain sample obtained
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)